Published in Head Neck on January 27, 2012
MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | NCT00257738
An updated overview of HPV-associated head and neck carcinomas. Oncotarget (2014) 1.06
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 1.01
The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med (2016) 0.93
Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol (2013) 0.93
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) (2015) 0.90
Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol (2013) 0.84
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother (2014) 0.84
New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol (2013) 0.80
Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma. J Clin Med (2015) 0.76
Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene. J Cancer Res Clin Oncol (2013) 0.76
Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma. Oncol Lett (2016) 0.75
Dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron (2017) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol (2005) 3.16
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 2.02
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res (2002) 1.57
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25
Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck (2006) 1.23
Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol (2000) 1.16
The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics (1995) 1.16
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res (2008) 1.13
Improving vaccine delivery using novel adjuvant systems. Hum Vaccin (2008) 1.05
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets (2007) 1.02
TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol (2001) 0.96
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol (2008) 0.94
Simultaneous detection of multiple single-base alleles at a polymorphic site. Biotechniques (1991) 0.93
Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res (2001) 0.92
Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck (2003) 0.91
Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol (1997) 0.90
Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med (2009) 0.86
Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother (1988) 0.85
Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer (2003) 0.84
Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother (2004) 0.83
Development and immunophenotyping of squamous cell carcinoma xenografts: tools for translational immunology. Laryngoscope (2005) 0.77
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
A test of climate, sun, and culture relationships from an 1810-year Chinese cave record. Science (2008) 3.94
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol (2007) 3.58
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol (2005) 2.55
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
From flies' eyes to our ears: mutations in a human class III myosin cause progressive nonsyndromic hearing loss DFNB30. Proc Natl Acad Sci U S A (2002) 2.17
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
What are the best management strategies for radiation-induced xerostomia? Laryngoscope (2013) 1.97
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol (2002) 1.97
Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest (2003) 1.87
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys (2007) 1.86
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
Role of glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem (2002) 1.82
HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene (2004) 1.82
Structural basis for the receptor binding specificity of Norwalk virus. J Virol (2008) 1.82
Effect of combined laser acupuncture on knee osteoarthritis: a pilot study. Lasers Med Sci (2008) 1.77
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol (2013) 1.67
Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant (2004) 1.64
Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg (2008) 1.63
Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation (2007) 1.56
TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. J Biol Chem (2008) 1.55
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol (2002) 1.51
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer (2010) 1.50
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res (2009) 1.49
Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol (2010) 1.46
Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys (2008) 1.46
BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl (2002) 1.43
Multiple mutations of MYO1A, a cochlear-expressed gene, in sensorineural hearing loss. Am J Hum Genet (2003) 1.43
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
Interacinar c4d staining in pancreas allografts. Transplantation (2009) 1.41
Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions. J Biol Chem (2007) 1.39
Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J Virol (2012) 1.38
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood (2010) 1.38
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol (2002) 1.36
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother (2011) 1.34
Prediction of antimicrobial peptides based on sequence alignment and feature selection methods. PLoS One (2011) 1.34
FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother (2008) 1.34
Functional analysis of the heat shock regulator HrcA of Chlamydia trachomatis. J Bacteriol (2002) 1.33
CPAF: a Chlamydial protease in search of an authentic substrate. PLoS Pathog (2012) 1.33
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.33
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32
Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32
Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog (2011) 1.31
Sigma28 RNA polymerase regulates hctB, a late developmental gene in Chlamydia. Mol Microbiol (2003) 1.29
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer (2004) 1.29
BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. Am J Transplant (2003) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician (2007) 1.27
Oral inflammatory myofibroblastic tumor: case report and review of literature. Open Dent J (2011) 1.26
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component. Diagn Pathol (2007) 1.26
Cryo-EM structure of a novel calicivirus, Tulane virus. PLoS One (2013) 1.26
Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control (2005) 1.25
Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol (2006) 1.25
Mutational analysis of the Chlamydia trachomatis dnaK promoter defines the optimal -35 promoter element. Nucleic Acids Res (2003) 1.24
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol (2012) 1.23
Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer (2009) 1.22
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf (2012) 1.21
Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol (2002) 1.21
Gfi1 and Gfi1b act equivalently in haematopoiesis, but have distinct, non-overlapping functions in inner ear development. EMBO Rep (2006) 1.21
Oral inflammatory myofibroblastic tumor demonstrating ALK, p53, MDM2, CDK4, pRb, and Ki-67 immunoreactivity in an elderly patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2005) 1.19
Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.19
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood (2008) 1.18
Rotavirus VP8*: phylogeny, host range, and interaction with histo-blood group antigens. J Virol (2012) 1.18